免疫检查点抑制剂加抗血管内皮生长因子/酪氨酸激酶抑制剂联合经动脉化疗栓塞术（三联疗法）治疗不可切除肝细胞癌 - Suppr

Suppr

超能文献

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

出版信息

Liver Cancer. 2024 Apr 17;13(3):227-234. doi: 10.1159/000538558. eCollection 2024 Jun.

DOI:10.1159/000538558

PMID:38894813

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11185853/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c289/11185853/6f12c2b09aa1/lic-2024-0013-0003-538558_F02.jpg

相似文献

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma.

Liver Cancer. 2024 Apr 17;13(3):227-234. doi: 10.1159/000538558. eCollection 2024 Jun.

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.

Cardiovasc Intervent Radiol. 2024 Jun;47(6):751-761. doi: 10.1007/s00270-024-03724-x. Epub 2024 Apr 26.

Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.

Acad Radiol. 2024 Apr;31(4):1304-1311. doi: 10.1016/j.acra.2023.09.001. Epub 2023 Sep 27.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun.

Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.

Front Immunol. 2023 Jul 31;14:1205636. doi: 10.3389/fimmu.2023.1205636. eCollection 2023.

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.

Front Oncol. 2022 Sep 28;12:980214. doi: 10.3389/fonc.2022.980214. eCollection 2022.

Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.

J Gastrointest Oncol. 2023 Aug 31;14(4):1837-1848. doi: 10.21037/jgo-23-486. Epub 2023 Aug 14.

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.

Front Immunol. 2022 May 23;13:913464. doi: 10.3389/fimmu.2022.913464. eCollection 2022.

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.

J Hepatocell Carcinoma. 2022 Nov 30;9:1217-1228. doi: 10.2147/JHC.S386672. eCollection 2022.

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.

Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231166765. doi: 10.1177/15330338231166765.

引用本文的文献

Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.

Ther Adv Med Oncol. 2025 Jul 24;17:17588359251357719. doi: 10.1177/17588359251357719. eCollection 2025.

Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.

Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf058.

Current Perspectives on Perioperative Combination Therapy for Hepatocellular Carcinoma.

Liver Cancer. 2025 Apr 29:1-21. doi: 10.1159/000546138.

Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity.

Bioact Mater. 2025 May 31;51:634-649. doi: 10.1016/j.bioactmat.2025.05.016. eCollection 2025 Sep.

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150.

Liver Cancer. 2025 Mar 3:1-16. doi: 10.1159/000544981.

The Prognostic Value of CRP/Alb Ratio in Predicting Overall Survival for Hepatocellular Carcinoma Treated with Transcatheter Intra-Arterial Therapy Combined with Molecular-Targeted Agents and PD-1/PD-L1 Inhibitors.

J Inflamm Res. 2025 Jan 8;18:203-217. doi: 10.2147/JIR.S483208. eCollection 2025.

Prognostic Prediction and Risk Stratification of Transarterial Chemoembolization Combined with Targeted Therapy and Immunotherapy for Unresectable Hepatocellular Carcinoma: A Dual-Center Study.

J Hepatocell Carcinoma. 2024 Nov 7;11:2169-2179. doi: 10.2147/JHC.S487080. eCollection 2024.

Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.

Curr Oncol. 2024 Sep 27;31(10):5821-5831. doi: 10.3390/curroncol31100432.

A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization).

Liver Cancer. 2024 May 13;13(4):335-343. doi: 10.1159/000539301. eCollection 2024 Aug.

本文引用的文献

A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.

Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb.

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

NEJM Evid. 2022 Aug;1(8):EVIDoa2100070. doi: 10.1056/EVIDoa2100070. Epub 2022 Jun 6.

Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.

Liver Cancer. 2023 Oct 3;12(6):497-509. doi: 10.1159/000534304. eCollection 2023 Dec.

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.

Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep.

Breakthroughs in Hepatocellular Carcinoma Therapies.

Clin Gastroenterol Hepatol. 2023 Jul;21(8):2135-2149. doi: 10.1016/j.cgh.2023.01.039. Epub 2023 Feb 20.

Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.

Liver Cancer. 2022 Oct 6;11(6):487-496. doi: 10.1159/000527404. eCollection 2022 Dec.

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.

Liver Cancer. 2022 Jul 27;11(5):399-406. doi: 10.1159/000526163. eCollection 2022 Sep.

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.

Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul.

New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.

Int J Clin Oncol. 2022 Jul;27(7):1110-1119. doi: 10.1007/s10147-022-02166-0. Epub 2022 May 8.

Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.

Liver Cancer. 2021 Dec 8;11(1):1-8. doi: 10.1159/000521374. eCollection 2022 Jan.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验